Disease landscape
Cystic Fibrosis
The limitations in access to cystic fibrosis treatment and diagnosis in the V4 region vary considerably between countries - and the distance between the highest scoring countries, Czechia and Poland, and the lowest scoring Hungary is approximately 25 points. Hungary's score is mainly influenced by the low proportion of patients treated with triple combination therapy and the overall score of all countries is compromiseded by the long time from registration to reimbursement.
Cross-Country
General GAP for Cystic Fibrosis
Compliance with guidelines
Clinical practice guidelines recommend the use of 5 the cystic fibrosis drugs considered in the project. Overall, at least 3 of them are available in V4 countries - compliance with the guidelines is assessed at 60%-100%.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
Estimated values.
There is no data for the EU and Western Europe average.
*disability adjusted life-years
Target population
kaftrio
Drug access
Number of patients treated (2023)
Drug access
Population treated (%)
Main issues
- The average time to regular reimbursement for cystic fibrosis drugs in the V4 countries is 5.2 years. The difference between the shortest and the longest mean time to reimbursement between the countries is 1.5 year.
- Financing of the triple combination CF therapy either in regular reimbursement and early access programmes was introduced in V4 states in 2021 and in 2022 in all countries with very different results: only around 24% of patients in the target population in Hungary get the treatment, compared to 74% in Slovakia and Poland and 93% of patients in Czechia.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).